Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Nerve Sheath Neoplasms

ClinicalTrials.gov lists 485 trials for Nerve Sheath Neoplasms or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 50.

MeSH D018317 Neoplasms Neoplasm C04 C10
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 59 Phase 1/2 Phase 1/2 32 Phase 2 Phase 2 116 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 21 Phase 4 Phase 4 8 Not applicable Not applicable 110 Observational Observational 129 Phase 1 Phase 1 59 Phase 1/2 Phase 1/2 32 Phase 2 Phase 2 116 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 21 Phase 4 Phase 4 8 Not applicable Not applicable 110 Observational Observational 129

Trials per phase (log scale)

1 more section with rows

15 of the 485 trials are tagged with Nerve Sheath Neoplasms itself; the rest are tagged with a narrower condition beneath it.

Get the Nerve Sheath Neoplasms report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Nerve Sheath Neoplasms trials start? (32)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 36

1995: 1 trials (Phase 3 1) 1996: 2 trials (Observational 1, Phase 3 1) 1997: 1 trials (Phase 3 1) 1998: 3 trials (Observational 1, Phase 3 1, Phase 2 1) 1999: 2 trials (Phase 2 2) 2000: 6 trials (Observational 1, Not applicable 2, Phase 2 1, Phase 1/2 1, Phase 1 1) 2001: 8 trials (Observational 3, Phase 2 3, Phase 1 2) 2002: 5 trials (Observational 1, Not applicable 1, Phase 2 2, Phase 1 1) 2003: 3 trials (Phase 3 1, Phase 2 2) 2004: 8 trials (Observational 3, Phase 4 1, Phase 3 1, Phase 2 2, Phase 1 1) 2005: 8 trials (Observational 3, Not applicable 1, Phase 3 1, Phase 2 3) 2006: 13 trials (Observational 3, Not applicable 2, Phase 3 1, Phase 2/3 2, Phase 2 4, Phase 1 1) 2007: 10 trials (Observational 4, Phase 3 2, Phase 2 4) 2008: 12 trials (Observational 4, Not applicable 1, Phase 2 3, Phase 1 4) 2009: 13 trials (Observational 1, Not applicable 2, Phase 3 1, Phase 2 4, Phase 1/2 1, Phase 1 4) 2010: 13 trials (Observational 4, Not applicable 2, Phase 2 2, Phase 1/2 2, Phase 1 3) 2011: 11 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2/3 1, Phase 2 3, Phase 1/2 2, Phase 1 2) 2012: 21 trials (Observational 9, Phase 4 1, Phase 2 7, Phase 1/2 1, Phase 1 3) 2013: 10 trials (Observational 1, Not applicable 5, Phase 2 1, Phase 1/2 2, Phase 1 1) 2014: 17 trials (Observational 2, Not applicable 7, Phase 2/3 2, Phase 2 5, Phase 1 1) 2015: 26 trials (Observational 8, Not applicable 4, Phase 4 2, Phase 3 1, Phase 2 4, Phase 1/2 3, Phase 1 4) 2016: 18 trials (Observational 6, Not applicable 5, Phase 2 7) 2017: 27 trials (Observational 9, Not applicable 7, Phase 2 9, Phase 1 2) 2018: 27 trials (Observational 11, Not applicable 6, Phase 4 1, Phase 3 1, Phase 2 6, Phase 1/2 1, Phase 1 1) 2019: 31 trials (Observational 10, Not applicable 12, Phase 4 1, Phase 2 6, Phase 1/2 1, Phase 1 1) 2020: 25 trials (Observational 4, Not applicable 6, Phase 3 3, Phase 2 5, Phase 1 7) 2021: 36 trials (Observational 10, Not applicable 8, Phase 3 1, Phase 2 8, Phase 1/2 3, Phase 1 6) 2022: 28 trials (Observational 7, Not applicable 11, Phase 4 1, Phase 2/3 1, Phase 1/2 3, Phase 1 5) 2023: 17 trials (Observational 6, Not applicable 3, Phase 3 1, Phase 2 4, Phase 1/2 2, Phase 1 1) 2024: 22 trials (Observational 5, Not applicable 7, Phase 4 1, Phase 2 6, Phase 1/2 2, Phase 1 1) 2025: 24 trials (Observational 5, Not applicable 6, Phase 3 1, Phase 2 6, Phase 1/2 3, Phase 1 3)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 28
2025 24
2024 22
2023 17
2022 28
2021 36
2020 25
2019 31
2018 27
2017 27

Showing 10 of 32 earlier years.

Start your 14-day trial Email me all 32 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 34 trials starting in 2026 and about 29 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 63 trials still running at the 2026-10-09 snapshot; registered median of 41 months across 270 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Nerve Sheath Neoplasms trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 59
Phase 1/2 32
Phase 2 116
Phase 2/3 6
Phase 3 21
Phase 4 8
Not applicable 110
Observational 129
Expanded access 4

How many Nerve Sheath Neoplasms trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 18
Recruiting 84
Enrolling by invitation 7
Active, not recruiting 38
Available 2

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Nerve Sheath Neoplasms trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 50
AstraZeneca 14
European Organisation for Research and Treatment of Cancer - EORTC 13
Novartis Pharmaceuticals 6

Which drugs are being tested for Nerve Sheath Neoplasms? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Selumetinib 23
EVEROLIMUS 8
Imatinib 7
GSK1120212 6
Lovastatin 5

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Doxorubicine 17
Ifosfamid 12
Radiation Therapy 7
Bevacizumab 1 7
Filgrastime (G-CSF) 4

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Nerve Sheath Neoplasms trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Vomiting 58 16
Dyspnea 49 9
Pleural effusion 48 10
Dehydration 41 16
Febrile neutropenia 39 6

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Nerve Sheath Neoplasms? (29)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA. Cancer discovery 2023 Yes
Imaging in gynecological disease (26): clinical and ultrasound characteristics of benign retroperitoneal pelvic peripheral-nerve-sheath tumors. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2023 Yes
Robotic Nerve Sheath Tumor Resection With Intraoperative Neuromonitoring: Case Series and Systematic Review. Operative neurosurgery (Hagerstown, Md.) 2022 Yes
Selinexor, a First in Class, Nuclear Export Inhibitor for the Treatment of Advanced Malignant Peripheral Nerve Sheath Tumor. The oncologist 2021 Yes
Systemic Options for Malignant Peripheral Nerve Sheath Tumors. Current treatment options in oncology 2021 Yes

Showing 5 of 29 publications.

Start your 14-day trial Email me all 29 publications as a PDF

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages